Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN22530 · 1 trial · 2 indications
Part A and B
Part C
| Arm | Type | Description |
|---|---|---|
| Phase 1 Part A | EXPERIMENTAL | - |
| Phase 1 Part B | EXPERIMENTAL | - |
| Phase 2 Part C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN22530 | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol 2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1 3. ...
REGN22530 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. for ophthalmology. It is in Phase 1 clinical development for Primary Open Angle Glaucoma (POAG) and ocular hypertension. It has not been approved by the FDA and remains under clinical study.
REGN22530 is being studied for Primary Open Angle Glaucoma (POAG) and ocular hypertension in adults. The Phase 1 trial enrolls adults 18 years and older in the United States. Because it is investigational, REGN22530 is not currently approved for any use.
REGN22530 is developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the Phase 1 program evaluating the small molecule in Primary Open Angle Glaucoma and ocular hypertension.
REGN22530 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program has one active trial, which is currently recruiting participants, and no completed trials to date.
REGN22530 is being evaluated in the Phase 1 trial NCT07675824, titled REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension. The trial is recruiting in the United States, is randomized, double blind, and controlled, and plans to enroll 271 participants.
The REGN22530 clinical program has one trial with a planned enrollment of 271 participants. That Phase 1 study, NCT07675824, is randomized, double blind, and controlled, and it is currently recruiting adults with Primary Open Angle Glaucoma or ocular hypertension in the United States.